DE69232616T2 - Saponin-antigen-konjugate und ihre verwendung - Google Patents

Saponin-antigen-konjugate und ihre verwendung

Info

Publication number
DE69232616T2
DE69232616T2 DE69232616T DE69232616T DE69232616T2 DE 69232616 T2 DE69232616 T2 DE 69232616T2 DE 69232616 T DE69232616 T DE 69232616T DE 69232616 T DE69232616 T DE 69232616T DE 69232616 T2 DE69232616 T2 DE 69232616T2
Authority
DE
Germany
Prior art keywords
saponin
antigen conjugates
saponins
conjugates
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69232616T
Other languages
English (en)
Other versions
DE69232616D1 (de
Inventor
Charlotte A Kensil
Sean Soltysik
Dante J Marciani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agenus Inc
Original Assignee
Antigenics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antigenics LLC filed Critical Antigenics LLC
Application granted granted Critical
Publication of DE69232616D1 publication Critical patent/DE69232616D1/de
Publication of DE69232616T2 publication Critical patent/DE69232616T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J17/005—Glycosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
DE69232616T 1991-09-18 1992-09-17 Saponin-antigen-konjugate und ihre verwendung Expired - Lifetime DE69232616T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76275491A 1991-09-18 1991-09-18
US07/906,880 US5583112A (en) 1987-05-29 1992-07-02 Saponin-antigen conjugates and the use thereof
PCT/US1992/007801 WO1993005789A1 (en) 1991-09-18 1992-09-17 Saponin-antigen conjugates and the use thereof

Publications (2)

Publication Number Publication Date
DE69232616D1 DE69232616D1 (de) 2002-06-27
DE69232616T2 true DE69232616T2 (de) 2002-09-05

Family

ID=27117183

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232616T Expired - Lifetime DE69232616T2 (de) 1991-09-18 1992-09-17 Saponin-antigen-konjugate und ihre verwendung

Country Status (12)

Country Link
US (1) US5583112A (de)
EP (1) EP0606317B1 (de)
JP (1) JP3717511B2 (de)
AT (1) ATE217795T1 (de)
AU (1) AU662562B2 (de)
CA (1) CA2118928C (de)
DE (1) DE69232616T2 (de)
DK (1) DK0606317T3 (de)
ES (1) ES2174837T3 (de)
NO (1) NO940949L (de)
NZ (1) NZ244410A (de)
WO (1) WO1993005789A1 (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273965A (en) * 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
US5650398A (en) * 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
CA2158651C (en) * 1993-03-29 2009-09-01 David S. Roberts Multicomponent clostridial vaccines using saponin adjuvants
FR2707646A1 (fr) * 1993-07-15 1995-01-20 Univ Toulouse Procédé d'extraction et de purification de saponines hémolytiques.
NL9301690A (nl) * 1993-08-12 1995-04-18 Seed Capital Investments Verbindingen met adjuvans-activiteit.
WO1995009179A1 (en) * 1993-09-30 1995-04-06 Seed Capital Investments (Sci) B.V. Compounds with adjuvant activity
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5597807A (en) * 1994-08-01 1997-01-28 University Of Saskatchewan Quinoa saponin compositions and methods of use
US5688772A (en) * 1994-08-01 1997-11-18 University Of Saskatchewan Quinoa saponin compositions and methods of use
US6080408A (en) 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US20010053365A1 (en) * 1995-04-25 2001-12-20 Smithkline Beecham Biologicals S.A. Vaccines
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US6300118B1 (en) 1995-06-07 2001-10-09 American Home Products Corporation Plasmids comprising a genetically altered feline immunodeficiency virus genome
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
EP0996451B1 (de) * 1997-05-20 2005-01-05 Galenica Pharmaceuticals, Inc. Triterpene-saponin analoga mit adjuvans und immunostimulierender wirkung
EP0988053A1 (de) * 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Gereinigte saponinen als orale adjuvantien
WO1999010008A1 (en) * 1997-08-29 1999-03-04 Aquila Biopharmaceuticals, Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
EP1027061B1 (de) * 1997-10-03 2005-05-25 Galenica Pharmaceuticals, Inc. Iminbildende polysaccharide, deren herstellung und verwendung als zusatzmittel und immunstimulierende mittel
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
WO1999055715A2 (en) 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
EP1104306B1 (de) * 1998-08-10 2006-01-11 Antigenics Inc. Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
US20010034330A1 (en) * 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
WO2000009075A2 (en) * 1998-08-14 2000-02-24 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
TW586935B (en) * 1998-09-14 2004-05-11 Kitasato Inst Saponin-containing vaccine preparation
DK2204186T3 (en) 1999-02-17 2016-07-18 Csl Ltd Immunogenic complexes, and related methods
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US20040146521A1 (en) * 1999-06-01 2004-07-29 Schenk Dale B. Prevention and treatment of synucleinopathic disease
AU7085400A (en) * 1999-09-02 2001-03-26 Antigenics, Inc. Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
DE60039715D1 (de) * 1999-11-19 2008-09-11 Csl Ltd Hcv-impfstoff zusammensetzungen
WO2001062893A2 (en) * 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
JP5059271B2 (ja) 2000-03-31 2012-10-24 パーデュー・リサーチ・ファウンデイション リガンド免疫原複合体を用いる処置方法
ATE442866T1 (de) * 2000-06-20 2009-10-15 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
ATE409495T1 (de) 2001-04-04 2008-10-15 Nordic Vaccine Technology As Polynukleotide-bindende komplexe die sterolen und saponine enthalten
CA2445826C (en) * 2001-05-02 2014-03-25 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
WO2003028634A2 (en) * 2001-09-28 2003-04-10 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
EP1467755A1 (de) * 2001-12-21 2004-10-20 Antigenics Inc. Immunreaktive reagentien und saponine enthaltende zusammensetzungen sowie verfahren zur verwendung davon
WO2003070187A2 (en) 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
SE0202110D0 (sv) * 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8697082B2 (en) * 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) * 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
AU2003300831A1 (en) * 2002-12-11 2004-06-30 Hawaii Biotech, Inc. Recombinant vaccine against flavivirus infection
US20050287170A1 (en) * 2002-12-11 2005-12-29 Hawaii Biotech, Inc. Subunit vaccine against West Nile viral infection
US7262027B2 (en) * 2003-03-14 2007-08-28 Medical College Of Ohio Polypeptide and DNA immunization against Coccidioides spp. infections
WO2004092329A2 (en) * 2003-04-08 2004-10-28 Galenica Pharmaceuticals, Inc. Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US8541002B2 (en) * 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
WO2007092299A2 (en) * 2006-02-03 2007-08-16 Purdue Research Foundation Targeted conjugates and radiation
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8153116B2 (en) 2006-07-11 2012-04-10 University Of Connecticut Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
US8128921B2 (en) * 2006-07-11 2012-03-06 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
US8147833B2 (en) * 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
JP5558834B2 (ja) * 2007-02-23 2014-07-23 ヤンセン アルツハイマー イミュノセラピー シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US20100172937A1 (en) * 2007-05-03 2010-07-08 Kotwal Girish J Enveloped virus neutralizing compounds
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CN101903037A (zh) * 2007-11-15 2010-12-01 恩多塞特公司 施用偶合物的方法
CN102112484B (zh) 2008-04-08 2015-03-04 索隆-基特林癌症研究协会 三萜皂苷、其合成方法和用途
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN101791410B (zh) * 2010-01-25 2013-03-27 中国药科大学 抗感染药物-多糖偶联物及其药物组合物的制备和应用
MD4177C1 (ro) * 2011-01-14 2013-02-28 Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова Metodă de vaccinare contra hepatitei virale B a persoanelor imunocompromise
AU2012308149A1 (en) 2011-09-12 2014-03-27 Sheena Mary Geraldine MCCORMACK Methods and compositions for raising an immune response to HIV
IL292991A (en) * 2017-04-25 2022-07-01 Adjuvance Tech Inc Triterpene saponin analogs
CA3124151A1 (en) * 2018-12-21 2020-06-25 Sapreme Technologies B.V. Saponin conjugates
WO2020210573A1 (en) * 2019-04-11 2020-10-15 Triterpenoid Therapeutics, Inc. Methods and compositions for irreversible enzyme inhibition
WO2021014019A1 (en) * 2019-07-25 2021-01-28 Sapreme Technologies B.V. Saponin derivatives with improved therapeutic window
WO2021014026A2 (en) 2019-07-25 2021-01-28 Sapreme Technologies B.V. Bioactive saponin linked to a functional moiety
JP2023532680A (ja) 2020-06-24 2023-07-31 サプリーム テクノロジーズ，ベー．フェー． 改善された治療濃度域を有するサポニン誘導体
AU2021321944A1 (en) 2020-08-07 2023-04-06 Access To Advanced Health Institute Purified saponins and chromatographic process for purification of same
WO2022055352A1 (en) * 2020-09-10 2022-03-17 Sapreme Technologies B.V. Semicarbazone-based saponin conjugate
WO2022164316A1 (en) * 2021-01-26 2022-08-04 Sapreme Technologies B.V. Semicarbazone-based saponin conjugate
WO2023038517A1 (en) * 2021-09-09 2023-03-16 Sapreme Technologies B.V. Semicarbazone-based saponin conjugate
EP4190359A1 (de) * 2021-12-03 2023-06-07 Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE Saponinbasierte adjuvantien und impfstoffe

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2456116A1 (fr) * 1979-05-11 1980-12-05 Sarget Lab Nouvelle saponine triterpenique derivee de la caulophyllogenine et ses applications therapeutiques
DE3040246C2 (de) * 1979-10-29 1985-01-10 Osaka Chemical Laboratory Co., Ltd., Osaka Sojasaponine A↓1↓ und A↓2↓ und ihre Verwendung
EP0058021A3 (de) * 1981-02-06 1982-10-27 Beecham Group Plc Pharmazeutische Präparate
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4789702A (en) * 1984-05-18 1988-12-06 Cetus Corporation Feline leukemia virus vaccine
CA1267087A (en) * 1985-02-14 1990-03-27 Nicolaas Visser Synthetic immunogen
FR2581877B1 (fr) * 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
ES2039229T3 (es) * 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
ZA872532B (en) * 1986-04-21 1987-11-25 Akzo Nv Combined vaccine
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
CA1331443C (en) * 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP0484403A4 (en) * 1989-07-27 1993-03-17 Univax Biologics Incorporated Lipid a analog/immunogenic carrier conjugates and the use thereof as vaccines
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
US5273965A (en) * 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins

Also Published As

Publication number Publication date
CA2118928C (en) 2005-07-05
NO940949D0 (no) 1994-03-16
AU2666492A (en) 1993-04-27
EP0606317A4 (en) 1995-12-20
NO940949L (no) 1994-05-16
AU662562B2 (en) 1995-09-07
NZ244410A (en) 1995-03-28
WO1993005789A1 (en) 1993-04-01
EP0606317B1 (de) 2002-05-22
US5583112A (en) 1996-12-10
JP3717511B2 (ja) 2005-11-16
CA2118928A1 (en) 1993-04-01
EP0606317A1 (de) 1994-07-20
ES2174837T3 (es) 2002-11-16
ATE217795T1 (de) 2002-06-15
DK0606317T3 (da) 2002-09-16
JPH07504156A (ja) 1995-05-11
DE69232616D1 (de) 2002-06-27

Similar Documents

Publication Publication Date Title
DE69232616D1 (de) Saponin-antigen-konjugate und ihre verwendung
ATE116993T1 (de) Saponin-hilfsmittel.
DK0686023T3 (da) Solfiltre indeholdende havreekstrakter
DE69109954T2 (de) Selbsthebender und nichtausladender Lehnstuhl.
DE3886760T2 (de) Monoklonale antikörper gegen menschliche interleukin-4 und die sie erzeugenden hybridomen.
AU7286887A (en) Antibody preparation directed against neoantigens in human c3 (complement factor 3) and the use and manufacture thereof
DE69824023D1 (de) Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind
BR9814432A (pt) Composições derivadas de mycobacterium vaccae e processo para seu uso
ITMI910095A1 (it) Struttura di castone per il fissaggio di pietre preziose e simili, su gioielli in genere
DE3751834T2 (de) Selbstantigen der primären lebercirrhose
EP0714510A4 (de) Für natürliche killerzellen spezifische antigene und sie identifizierende antikörper
TR199800575T1 (en) Kemokin �-8'in k�sa formlar�.
DE69202417T2 (de) Eingekapselte Verglasung und Einsatzteil verwendet in dieser Verglasung.
FR2626155B1 (fr) Fauteuil multifonction et multiposition
EP0551308A4 (en) Novel peptide antigens and immunoassays, test kits and vaccines using the same
DE69111545D1 (de) Verbundfolie und Karte.
MX9205556A (es) Mejoras en composiciones novedosas que comprenden pentafluoroetano y monoclorodifluorometano.
AU2412692A (en) Novel peptide antigens and immunoassays, test kits and vaccines using the same
IT220317Z2 (it) Complesso di stecchetto-dolce in particolare lecca lecca, ghiacciolo e/o simili
KR920011049U (ko) 등받이가 개폐되는 야외용 의자
ITMI910467U1 (it) Rivestimento di gallerie mediante l'impiego di lastre in policarbonato e mezzi adatti allo scopo.
NO176743C (no) Stillbar sitte- og liggestol
IT9045719A0 (it) Dispositivo di irrigidimento e di correzione della planarita' di elementi planari rettangolari particolarmente di ante di mobili e simili
DE69710476D1 (de) Alkaloidglykoside zur verwendung als arzneimittel
BR9300081A (pt) Arranjo de gemas e/ou similares na composicao de pecas de adorno pessoal e/ou outras

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 606317

Country of ref document: EP